17,261 trials
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Solicited Injections Site or Systemic Reactions Following Vaccination at Day 0: Aged 10-18 Years — 59; 51; 50; 49 Participants
Leukemia
Primary: Median Progression-free Survival (PFS) for Patients Less Than 60 Years of Age — 52.1 months
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Chronic Stable Heart Failure
Primary: Number of Patients With Adverse Events, Serious Adverse Events and Death — 1; 2; 4; 7 Participants
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) of Vorinostat — 230 mg/m^2
Metastatic Breast Cancer · Brain Metastases
Primary: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) — 88.9 percentage of participants
Lymphoma, Non Hodgkin
Primary: Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population — 2; 3; 5; 0 Participants
Multiple Myeloma
Primary: Overall Response Rate After 4 Cycles — 4; 3; 32; 21 Participants
Major Depressive Disorder
Primary: Mean Time of Retention — 27.08; 25.84 weeks
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Somatostatin Analogs · Polycystic Liver Disease · Autosomal Dominant Polycystic Kidney Disease
Primary: Change in Liver Volume — -3.36; 6.29 percentage of change — p=0.001
Diabetes Mellitus, Type 1
Primary: Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months. — 0.528; 0.646; 0.406 nmol/L
Asthma
Primary: Percentage of Participants With Loss of Asthma Control Over Weeks 0-16 — 81; 67 Percentage of participants
Bacterial Recovery of Skin Flora Post-product Application
Primary: Measurement of Skin Flora Recovery Post-prep Application — 1.39; 1.15; 1.97; 1.82 log10 CFU/cm^2 — p=0.13
Idiopathic Pulmonary Fibrosis (IPF)
Primary: Number of Participants With Adverse Events (AEs) — 6; 5; 6; 4 Participants